Point72 Asia Singapore Pte. Ltd. Makes New $65,000 Investment in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Point72 Asia Singapore Pte. Ltd. bought a new position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) during the second quarter, Holdings Channel reports. The institutional investor bought 11,612 shares of the specialty pharmaceutical company’s stock, valued at approximately $65,000.

A number of other large investors have also recently bought and sold shares of the business. Headlands Technologies LLC increased its stake in shares of Eagle Pharmaceuticals by 75.7% in the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 2,861 shares during the period. Fidelis Capital Partners LLC acquired a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at approximately $71,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at approximately $76,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of Eagle Pharmaceuticals in the first quarter valued at approximately $83,000. Finally, Aristides Capital LLC acquired a new stake in shares of Eagle Pharmaceuticals in the fourth quarter valued at approximately $86,000. Institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of NASDAQ:EGRX opened at $3.95 on Monday. The stock has a market capitalization of $51.30 million, a price-to-earnings ratio of 3.35 and a beta of 0.53. Eagle Pharmaceuticals, Inc. has a 1-year low of $3.21 and a 1-year high of $15.91. The company has a 50 day moving average price of $4.50 and a 200 day moving average price of $4.65.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Eagle Pharmaceuticals in a research note on Thursday. They set a “hold” rating on the stock.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.